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Generation of a Kupffer Cell-evading Adenovirus
for Systemic and Liver-directed Gene Transfer
Reeti Khare1, Shannon M May2, Francesco Vetrini3, Eric A Weaver2, Donna Palmer3, Amanda Rosewell3,
Nathan Grove3, Philip Ng3 and Michael A Barry2,4
1
Virology and Gene Therapy Program, Mayo Graduate School, Rochester, Minnesota, USA; 2Translational Immunovirology and Biodefense Program,
Division of Infectious Diseases, Mayo Clinic, Rochester, Minnesota, USA; 3Department of Molecular and Human Genetics, Baylor College of Medicine,
Houston, Texas, USA; 4Department of Immunology, Department of Molecular Medicine, Mayo Clinic, Rochester, Minnesota, USA

As much as 90% of an intravenously (i.v.) injected dose of
adenovirus serotype 5 (Ad5) is absorbed and destroyed by
liver Kupffer cells. Viruses that escape these cells can then
transduce hepatocytes after binding factor X (FX). Given
that interactions with FX and Kupffer cells are thought to
occur on the Ad5 hexon protein, we replaced its exposed
hypervariable regions (HVR) with those from Ad6. When
tested in vivo in BALB/c mice and in hamsters, the Ad5/6
chimera mediated >10 times higher transduction in the
liver. This effect was not due to changes in FX binding.
Rather, Ad5/6 appeared to escape Kupffer cell uptake
as evidenced by producing no Kupffer cell death in vivo,
not requiring predosing in vivo, and being phagocytosed
less efficiently by macrophages in vitro compared to Ad5.
When tested as a helper-dependent adenovirus (Ad) vector, Ad5/6 mediated higher luciferase and factor IX transgene expression than either helper-dependent adenoviral
5 (HD-Ad5) or HD-Ad6 vectors. These data suggest that
the Ad5/6 hexon-chimera evades Kupffer cells and may
have utility for systemic and liver-directed therapies.
Received 12 October 2010; accepted 20 March 2011; published online
19 April 2011. doi:10.1038/mt.2011.71

Introduction
Adenovirus serotype 5 (Ad5) is widely used for liver gene transfer
studies because of its natural tropism for this organ after systemic
administration. Recent evidence suggests that this liver tropism is
dependent on the major capsid protein, hexon, which can bind host
serum coagulation factors to enhance hepatocyte transduction.1
More specifically, it was demonstrated that vitamin K dependent
blood factors VII, IX, X, and protein C enhance transduction of
Ad5.1–3 Factor X (FX) was found to bind Ad5 hexon with particularly high affinity using its γ-carboxyglutamate domain.4 Cryoelectron microscopy and hexon mutagenesis techniques localized
FX binding to the hypervariable (HVR) domains of Ad5 hexon.5,6
Adenoviral serotypes possess seven HVR domains that differ
widely in sequence, and in part, define them.7 As such, variations
in the HVR domain across serotypes and their differences in FX
binding affinity generally correlate with the ability of adenovirus
(Ad) serotypes to transduce hepatocytes.4

In addition to viral tropism, HVR domains may have a role in
sequestration of Ad virions within Kupffer cells. Kupffer cells are
resident liver macrophages that sequester 90% of the intravenously
(i.v.) injected Ad5 doses, thus representing a major barrier hepatocellular gene transfer.8 Although Kupffer cells comprise only ~7%
of liver cells,9 they are thought to represent 80–90% of all macrophages in the body10 and therefore represent a significant whole
body pharmacological “sink” for systemically administered Ad5.
In addition, Kupffer cells are antigen-presenting macrophages.
Therefore, rampant uptake of viral antigens into these cells may
amplify immune responses against the vector.
Uptake by Kupffer cells not only depletes circulating Ad5
but it kills these cells themselves.11 Kupffer cells can be destroyed
by “predosing” animals first with a high dose of irrelevant Ad5.
Four hours later, the therapeutic or reporter-expressing Ad can
be injected thereby avoiding destruction by the Kupffer cells.
Predosing is remarkably effective and, in the absence of the
Kupffer cell sink, virus escapes to other sites as evidenced by its
ability to increase hepatocyte expression 40-fold and its ability to
increase killing of distant tumor sites.12
In previous work testing systemic delivery of oncolytic Ads, a
series of viruses were tested for their ability to mediate this predosing effect.13 Surprisingly, species C Adenovirus serotype 6 (Ad6)
demonstrated remarkably less efficient predosing as compared to
the extensively studied species C Ad5. This data suggested that
Ad5 and Ad6 might have distinctly different interactions with
liver cells despite their high sequence identity.
Most of the sequence variation between Ad5 and Ad6 is in
the HVR domains of their hexon proteins.14 Given this, we have
tested whether this region mediates interactions with liver cells
by replacing the HVR domains of Ad5 with those from Ad6.
Comparison of this Ad5/6 vector with Ad5 vector after i.v. injection, demonstrates remarkable differences in their pharmacology
and interactions with macrophages and Kupffer cells.

Results
Generation of a hexon-chimeric Ad5/6 vector
Given that FX and Kupffer cell interactions are thought occur in the
HVR domains of hexon, we replaced the HVR region of Ad5 with
that of Ad6. PCR was used to clone the HVR region of Ad6 with
terminal ApaI and PstI restriction sites and this was used to replace
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Intravenous injection of mice with Ad5/6GL
generates higher liver expression when
compared to Ad5GL
1 × 1010 vp of Ad5GL or Ad5/6GL was injected into female BALB/c
mice by three different routes: intramuscular (i.m.), intranasal
(i.n.), and i.v. by tail vein (Figure 1). Luciferase imaging 24 hours
later demonstrated that both vectors mediated comparable expression when injected i.n. By the i.m. route, Ad5GL generated twofold higher expression than Ad5/6GL. In stark contrast, Ad5/6GL
produced >tenfold higher expression in the liver after i.v. injection
of equal particle numbers. Considering that the Ad5/6 has a lower
infectious unit titer, this tenfold increase likely underestimates
Ad5/6 activity. The comparison was repeated four times with several different viral preparations with essentially identical results.
That Ad5/6GL demonstrates lower nasal and muscle transduction
but higher liver expression indicates a unique biology with respect
to systemic delivery and liver infection.
FX binds to Ad5/6GL and is crucial for
hexon-mediated transduction of Ad5/6GL in vitro
The binding of Ad5 hexon to vitamin K dependent blood factors,
particularly FX, has been shown to traffic virions to hepatocytes
in vivo.2,5 Hexon protein was purified from Ad5GL or Ad5/6GL
infected cell lysates, immobilized on biosensor chips, and tested
for binding to human FX using Surface Plasmon Resonance
(Supplementary Table S2). Consistent with previous work,4
Ad5 hexon bound FX with high affinity (KD = 1.68 × 10−9 mol/l).
In contrast, FX affinity for Ad5/6 hexon was tenfold lower
(KD = 1.63 × 10−8 mol/l). Closer inspection revealed that association
(Ka) of unmodified and chimeric hexon with FX was similar, but the
latter appeared to dissociate (Kd) more rapidly. These results were
consistent with the binding kinetics of Ad6 to FX (Supplementary
Table S2). As previously shown, immobilization of FX on the chip
instead of hexon increased the KD by approximately tenfold.4
To assess functional FX binding in vitro, Ad5GL and Ad5/6GL
were tested for their ability to transduce cells that are nonpermissive for Ad5 infection. SKOV3 and CHO cell lines have low
levels of CAR, the coxsackie and adenovirus receptor,13 but in
Molecular Therapy vol. 19 no. 7 july 2011
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the corresponding HVR cassette in Ad5. Ad5/6GL expressing the
eGFP-luciferase (GL) reporter protein was generated by replacing this region of Ad5GL by red recombination (Supplementary
Figure S1). Replacing the Ad5 HVR domain with that of Ad6 significantly decreased the number of charged residues in this region.
Ad5 contains 31 negatively charged amino acids (blue; aspartic
acid and glutamic acid) and 17 positively charged amino acids
(red; arginine, histidine, and lysine). Ad6 displays only 25 negatively and 12 positively charged residues (Supplementary Figure
S1a). Both vectors retain the glutamic acid 451 (E451) in HVR7
that is conserved in all FX-binding Ads.6
Ad5/6GL and Ad5GL vectors grew with similar kinetics,
although Ad5/6GL yielded approximately fivefold fewer virus particles (vp) and sevenfold fewer plaque forming units after purification (Supplementary Table S1). Western blotting of Ad5GL
and Ad5/6GL with serum from Ad5 and Ad5/6-immunized mice
demonstrated that these antibodies did not crossreact against each
other’s hexon proteins (data not shown).
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Figure 1 In vivo expression of unmodified and chimeric adenoviruses
when injected via different routes. BALB/c mice were injected with
1 × 1010 virus particles of either Ad5GL or Ad5/6GL by different routes.
(a) Mice were imaged 24 hours later using a Lumazone imager: intranasal,
10-minute 1 × 1 binning, 1,315–1,389 gray values; intramuscular, 10-minute
2 × 2 binning, 712–1,300 gray values; intravenous, 1 minute 1 × 1 binning,
1,296–2,000 gray values. Shown are representative white light images
overlaid with luciferase expression in pseudo-color. (b) Quantification of
luciferase expression in mice injected via different routes after 24 hours.
N = 5. *P < 0.05; ns = not significant. Means ± SEM.

the presence of FX, Ad5 is able to transduce these cells.4,6 Both
viruses were incubated on cells in the presence or absence of
physiological levels of FX (10 µg/ml) for 3 hours at 37 °C, and
were assayed for transduction by luciferase activity 24 hours later
(Figure 2a,c). Transgene expression by both viruses increased
significantly in the presence of FX. When tested on CHO cells
expressing CAR, the FX effect was masked (Figure 2b).

Vitamin K dependent blood clotting factors are
crucial for liver transduction by Ad5/6GL in vivo
Warfarin inhibits vitamin-K mediated γ-carboxylation of blood
factors such as FX, decreasing their ability to retarget Ad5 to hepatocytes.12,15 To test if blood factors mediated Ad5/6GL liver transduction in vivo, BALB/c mice were treated with warfarin prior to
i.v. injection of both viruses (Figure 2d). For both, warfarinization
dramatically decreased luciferase expression in the liver. The fold
decrease between mice after warfarinization was twofold for Ad5
and 18-fold for Ad5/6.
Ad5/6GL is less efficiently phagocytosed
by macrophages in vitro
Phagocytic Kupffer cells are a considerable sink for i.v. injected
Ad5 particles. To test whether the Ad6 HVRs changed recognition of Ad virions by phagocytic cells, the viruses were incubated
1255
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Figure 2 Ad5/6GL and Ad5GL interact with blood factors comparably. (a) CHO, (b) CHO cells transiently transfected with coxsackie-adenovirus
receptor (CAR), or (c) SKOV3 were infected with unmodified or chimeric adenovirus (Ad) vectors (multiplicity of infection 1,000) ± FX (10 µg/ml).
A luciferase assay was performed after 24 hours to determine transgene expression. N = 6. (d) BALB/c mice were injected subcutaneously with warfarin (133 µg in 100 µl peanut oil) 3 and 1 day before intravenous injection of 1 × 1010 virus particles (vp) unmodified or chimeric adenoviruses. Mice
were imaged 24 hours later using a Lumazone imager and quantified for luciferase transgene expression; 3 minutes 2 × 2 binning. N = 5. *P < 0.05;
**P < 0.005; ns = not significant. Means ± SEM.
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Figure 3 Ad5/6GL is taken up into macrophages less than unmodified Ad5GL. (a) adenovirus (Ad) vectors were added to RAW 267.4 cells (multiplicity of infection 10,000). Cells were harvested 24 hours later and genomic DNA was extracted. Real-time PCR was used to quantify viral and cellular genomes using cytomegalovirus (CMV) and GAPDH specific primers, respectively. Data are normalized to cellular genomes. N = 4. BALB/c mice
were predosed intravenous (i.v.) with 3 × 1010 virus particles (vp) in 100 µl in phosphate-buffered saline (PBS). After 4 hours, the mice were injected
with 1 × 1010 vp in PBS of unmodified or chimeric Ad vector. Mice were imaged and luciferase expression was quantified (b) 24 hours after Ad vector
injection and (c) over time. N = 5. (d) Varying doses of Ad vectors were injected i.v. into mice. After 1 hour, mice were euthanized and 20 ng of tissue
from the large liver lobe was harvested. Total DNA was extracted and real-time PCR was used to quantify viral genomes using CMV primers. *P < 0.05;
**P < 0.005; ns = not significant. Means ± SEM.
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Ad5/6GL evades Kupffer cells for increased
liver expression in vivo
The in vitro RAW cell data suggested that swapping the Ad5
HVR for Ad6 HVR reduced phagocytosis by macrophage cells.
To explore this in vivo, mice were predosed by i.v. injection of
3 × 1010 vp of Ad5-dsRed to destroy Kupffer cells and prevent
trapping of subsequent doses of Ad.11 Four hours later, predosed
or control mice were injected i.v. with either Ad5GL or Ad5/6GL
and luciferase expression was measured over the following 10
days (Figure 3b,d). Consistent with previous data, predosing
with Ad5 increased subsequent transduction by Ad5GL by tenfold.12,13 In contrast, predosing did not increase liver expression
by Ad5/6GL. Liver tissue from mice injected with varying doses
of Ad vectors was harvested analyzed by real-time PCR for viral
genomes. Despite dramatic changes in liver expression, numbers

Number of cells/mm2

250
200

**

150

of viral genomes 1 hour (Figure 3c) and 24 hours (data not shown)
between the two vectors were similar.
Elimination of Kupffer cells by predosing above suggested that
Ad5 was being trapped by Kupffer cells while Ad5/6 is not. Since it
has been previously shown that Ad5 subsequently causes extensive
Kupffer cell depletion, we hypothesized that Ad5/6 would induce
less Kupffer cell death. To test this, mice were injected i.v. with
phosphate-buffered saline (PBS), a low dose (1 × 1010 vp) or a high
dose (3 × 1010 vp) of either Ad5 or Ad5/6. Six hours later, the large
liver lobes of the liver were harvested and immunohistochemistry
for F4/80 was performed to detect Kupffer cells (Figure 4). Six
hours after injection, the high dose of Ad5 caused a 20-fold reduction in F4/80+ cells while Ad5/6 caused only a threefold decrease
(Figure 4b). These data suggested that in the hours after injection,
Ad5/6 causes less loss of Kupffer cells from the liver than Ad5.
When Kupffer cells are killed by Ad5, they release lactate
dehydrogenase (LDH) into the blood within 30 minutes of
virus injection.11 To test this, Ad5 and Ad5/6 were injected at
increasing doses into mice and LDH levels were measured in

a
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with RAW 264.7 murine monocyte-macrophage cells in vitro.
Although we determined low levels of expression in vitro (data
not shown) these cells are thought to predominantly phagocytose
rather than endocytose Ad.16 Given this, phagocytosis was assessed
by incubating the cells with 10,000 vp/cell of Ad5 or Ad5/6 and
after 24 hours, viral genomes were quantified by real-time PCR
(Figure 3a). This analysis revealed that ~50% less Ad5/6GL viral
genomes were taken up into RAW macrophages when compared
to unmodified Ad5GL.
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Figure 4 Ad5/6 depletes Kupffer cells less than Ad5. BALB/c mice were
injected intravenous (i.v.) with phosphate-buffered saline, a low dose
[1 × 1010 virus particles (vp)], or a high dose (3 × 1010 vp) of adenovirus (Ad)
vectors. Six hours later, the large lobe of the liver was harvested, paraffin
embedded and sectioned (4 µm thick). (a,c–f) Immunohistochemical staining of Kupffer cells (anti-F4/80 macrophage marker). (b) Quantification of
F4/80 positive cells 6 hours after i.v. injection of Ad vectors. **P < 0.005;
ns = not significant. Means ± SEM.
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Figure 5 Ad5/6 demonstrates reduced toxicity in vivo. (a) BALB/c
mice were injected intravenous with up to 1 × 1011 virus particles (vp) of
adenovirus (Ad) vectors. Serum was harvested 30 minutes later and analyzed for lactate dehydrogenase levels. N = 3. BALB/c mice were injected
intravenously with 2.5 × 1011 vp of Ad vectors. (b) Serum was harvested
at 72 hours and assayed for alanine aminotransferase (ALT) levels. N = 3.
(c) Serum was harvested at 6 hours and assayed for interleukin-6 levels
(IL-6). N = 3. **P < 0.005; ns = not significant. Means ± SEM.
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Figure 6 Effect of Ad5/6GL in C57Bl/6 mice and Syrian hamsters. 1 × 1010 virus particles (vp) of Ad5GL or Ad5/6GL was injected intravenously
into C57BL/6 mice and intrajugularly into Syrian hamsters. (a) Mice were imaged for luciferase expression after 24 hours for 3 minutes at 2 × 2
binning (N = 10). (b,c) Hamsters were imaged after 4 days for 10 minutes at 2 × 2 binning (N = 4). Shown are (c) white light images overlaid with
luciferase expression in pseudo-color from 688 to 1400 gray values and (b) quantification of luciferase expression. *P = 0.05; ns = not significant.
Means ± SEM.

serum harvested 30 minutes later (Figure 5a). Under these conditions, LDH levels rose with increasing doses of Ad5GL virus.
In contrast, even the highest dose of Ad5/6GL did not increase
LDH levels, indicating that Kupffer cells remained viable at least
at 30 minutes. The threefold loss of F4/80+ cells observed in
Figure 4 at 6 hours suggests that Ad5/6 may cause lower toxicity than Ad5 and that this may manifest later than 30 minutes
after injection.

Ad5/6GL reduces toxicity
Ad5/6 appears to cause less Kupffer cell death which might impact
the release of inflammatory mediators by these phagocytic cells
and reduce liver damage. To test this, high doses of each vector
(2.5 × 1011 vp) were injected i.v. into BALB/c mice and blood was
harvested at 72 hours later to measure hepatocyte damage by
release of alanine aminotransferase (ALT) into the blood. While
both viruses produced relatively low liver damage (Figure 5b),
ALT levels were significantly lower by Ad5/6GL than Ad5GL.
Changes in Kupffer cell uptake and systemic cell transduction
might also modify the innate immune response to the viruses.
To test this, blood was also drawn 6 hours after injection of the
high dose viruses and interleukin-6 (IL-6) levels were assayed
(Figure 5c). In this case, IL-6 levels were similar suggesting
1258

that systemic innate immune responses are not overtly different
between Ad5 and the Ad5/6 chimera.

Ad5/6GL does not increase liver expression
in C57BL/6 mice
C57BL/6 mice are a fortuitous negative control for Kupffer effects
on Ad. When C57BL/6 mice are injected with equal doses of
Ad5, gene expression is significantly higher than in BALB/c mice.
This effect is due in part to 20 times as many Ad genomes being
sequestered in Kupffer cells in BALB/c mice than in C57BL/6
mice.17 Given this, we compared Ad5 and Ad5/6 in C57BL/6 mice
after i.v. injection (Figure 6a). In these mice, the Ad5/6 chimera
showed no enhanced luciferase activity consistent with reduced
Kupffer cell uptake in these mice.
Ad5/6GL increases liver expression in hamsters
Syrian hamsters are thought to be an optimal model for Ad5 biology, since these animals support Ad5 infection better than mice.18
To determine whether Ad5/6 activity was a peculiarity of BALB/c
mice, 1 × 1010 vp of Ad5 and Ad5/6 were injected intrajugularly
into Syrian hamsters (Figure 6b,c). Consistent with the BALB/c
model, Ad5/6GL generated threefold greater luciferase expression
in the liver compared to Ad5GL. This data suggests that Kupffer
www.moleculartherapy.org vol. 19 no. 7 july 2011
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cell uptake of Ad5 and improved transduction by Ad5/6 is a common effect across different species.
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Figure 7 In vivo expression of unmodified and chimeric helper dependent vectors. BALB/c mice were injected with 1 × 1010 virus particles
(vp) of either HD-Ad5GL or HD-Ad5/6GL by different routes. Mice were
imaged 24 hours later using a Lumazone imager for 3 minutes at 1 × 1 binning, 1,320–1,600 gray values. Shown are (a) white light images overlaid
with luciferase expression in pseudo-color. (b) Quantification of luciferase
expression. Intramuscular, left and intravascular, right. N = 5. **P < 0.005;
ns = not significant. Means ± SEM.
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Helper-dependent Ad5, Ad6, and Ad5/6 vectors
Helper-dependent adenoviral (HD-Ad) vectors have improved
safety profiles and extended expression when compared to replication defective (RD) Ad vectors.19–21 To test whether the hexon
chimera modified HD-Ad vector biology, an HD-Ad5 vector
expressing eGFP-luciferase was packaged by Ad5, Ad5/6, and
Ad6 helper viruses.22 In vitro comparison of transduction of A549
cells by HD-Ad5, Ad5/6, and Ad6 by luciferase assay confirmed
that all three helper dependent vectors transduced A549 cells to
a similar degree, although transduction was fourfold less than
that the first generation Ad5 and Ad5/6 vectors (data not shown).
HD-Ads were injected i.v. into BALB/c mice and imaged 24 hours
later (Figure 7). Consistent with the RD vectors, HD-Ad5/6GL
expressed 2.5-fold more luciferase in the liver than HD-Ad5.
Interestingly, HD-Ad5/6 also demonstrated ~1.7-fold greater
luciferase expression than HD-Ad6.
To test whether the chimera might have utility for liver gene
therapy for hemophilia, a helper-dependent vector expressing
human Factor IX (hFIX) transgene from a hepatocyte-specific
promoter was also packaged with Ad5, Ad5/6, and Ad6 helper
viruses. When injected into BALB/c mice, HD-Ad5/6-hFIX
produced approximately threefold and approximately twofold
higher levels of serum hFIX after 1 week when compared to both
HD-Ad5 and HD-Ad6, respectively (Figure 8a). This statistical
trend continues for at least 3 weeks (Figure 8b). These data suggest that the Ad5/6 chimeric virus may have utility for long-acting
HD-Ad-based liver-directed gene therapy.

Discussion
It is widely known that Ad5 rapidly localizes to the liver after systemic administration, thus highlighting its potential use as a liver
gene therapy vector. Ad5 hexon binds circulating FX with high
affinity, which then acts as a “molecular bridge” for binding to
hepatocytes.4,5,23 Another species C adenovirus, Ad6, was reported
to have a similar affinity for FX,4 but a potentially different interaction with Kupffer cells.13 We genetically replaced the Ad5 HVR
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Figure 8 Expression of hFIX from intravenous (i.v.) injection of helper dependent adenovirus (Ad) vectors. Helper dependent (HD) vectors
were injected intravenously into BALB/c mice at 2.5 × 1010 virus particles (vp)/mouse. Serum was harvested on (a) day 7 and (b) up to day 21. Serum
was analyzed for human Factor IX by enzyme linked imunosorbent assay. N = 5 for Ad5 and Ad5/6; N = 4 for Ad6. **P < 0.005; ns = not significant.
Means ± SEM.
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cassette with that of Ad6 in order to study the role of this region
in liver transduction.
When injected i.v. into BALB/c mice, Ad5/6 exhibited a tenfold
increase in liver expression compared to Ad5, but lower expression
when injected i.m. or i.n. In vitro functional assays confirmed the
role of vitamin K dependent blood factors in both Ad5 and Ad5/6
hepatocyte transduction, and in vivo ablation of blood factors with
warfarin reduced liver transduction for both vectors. This implies
the necessity of FX binding for liver tropism, although despite the
injection of warfarin, Ad5/6 expression remained higher than that of
Ad5. Moreover, surface plasmon resonance (SPR) analysis revealed
that Ad6 and Ad5/6 had lower affinity of for FX compared to Ad5.
These results indicate that the interaction of Ad5/6GL with blood
factors is just sufficient for cell binding and liver tropism, but is
unlikely to be the underlying cause of increased liver transduction.
Within the liver, Kupffer cells take up the majority of systemically injected Ad5 via scavenger receptors.8,24 Scavenger receptors
are thought to recognize charge clusters,25 it is therefore interesting that 20% of the amino acids in Ad5 HVR loops is either negatively charged (D, E) or positively charged (H, K, R). For example,
HVR1 has a net negative charge of 13. Conversely, Ad6 HVR1 has
net negative charge of only eight or five fewer than Ad5. When all
720 hexons are considered in aggregate, we hypothesized that this
40% decrease in charge could significantly decrease recognition of
Ad5/6 by Kupffer cells.
Consistent with this, Ad5/6 was phagocytosed 50% less efficiently than Ad5 by macrophages in vitro. In vivo, we show by three
assays that Ad5/6 interacts with Kupffer cells to a lower degree
than Ad5. First, eliminating Kupffer cells by predosing before Ad
vector injection conferred no increase in liver transduction for
Ad5/6, while Ad5 received a marked boost. Second, we show by
immunohistochemistry that a high dose of Ad5 depletes Kupffer
cells dramatically by 20-fold, while Ad5/6 decreases Kupffer cells
by only threefold. Finally, we show Ad5 killed Kupffer cells in a
dose-dependent fashion as measured by LDH release. On the
other hand, Ad5/6 generated constant levels of LDH even at high
doses, although increased variability in LDH measurements at
higher doses may indicate some Kupffer cell killing. These data
indicate that the Ad6 HVRs appear to interact to a significantly
lesser degree with Kupffer cells in vivo.
Ad5 and Ad5/6 were compared in RD vectors, but the effect
of RD-Ad6 was not measured due to the lack of a RD Ad6 vector
containing the luciferase transgene. Instead, the Ad5, 6, and 5/6
were compared in HD-Ad vectors. A luciferase assay showed that
HD-Ad vectors showed at least twofold decreased transduction
in vitro (data not shown). Nevertheless, HD-Ad5/6 demonstrated
significantly increased liver expression compared to Ad5, although
the fold increase was not as large. It was interesting to observe
that Ad5/6 was also better at transducing liver than Ad6. This may
have resulted from the longer fiber shaft of the Ad5 fiber, which is
generally more efficient compared to the shorter fiber of Ad6.14,26
Fiber shaft length may also explain why HD-Ad6 exhibited such
poor expression in muscle compared to HD-Ad5 or HD-Ad5/6.
Ad5/6 showed markedly increased expression in BALB/c
mice and Syrian hamsters. Interestingly, Ad5/6 had no benefit
in C57BL/6 mice. Recently, Vigant et al. also found differences
in behavior between hexon-modified Ad5 vectors in these two
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mice strains.27 Snoeys et al. determined that the overall number
of Kupffer cells between the two mouse strains is not significantly different, but consistent with our data, BALB/c mice take
up approximately sixfold more Ad DNA in their nonparenchymal cells than C57BL/6 mice, although both mice take up large
quantities of virus.17 When analyzed by cell type, they showed
that BALB/c Kupffer cells took up ~20 times more Ad DNA than
C57BL/6 cells after an i.v. injection of the vector. Since endothelial
cells also express scavenger receptors,28,29 fundamental differences
in the location, types, and/or density of these receptors between
animals may also explain why Ad5 and Ad5/6 expressed similarly
in C57BL/6 mice. Variations in scavenging and sequestration of
vectors beyond Kupffer cells (i.e., in hepatocytes endothelial cells,
blood cells, etc.) may also explain why the ALT hepatotoxicity levels were twofold greater in Ad5 compared to Ad5/6.
When adenoviruses from species B, C, and D were tested for
Kupffer uptake and hepatocyte infection, the species B and D
viruses appeared to evade both cell types.13 While this makes them
potentially excellent for systemic therapies that need to avoid the
liver, it also obviates their use for efficient liver-directed gene therapy. Conversely, species C viruses are able to infect hepatocytes,
but are also absorbed by Kupffer cells to varying degrees. The
Ad5/6 chimera appears to bridge these two biologies by evading
Kupffer cells while still being able to efficiently infect liver hepatocytes. Evading Kupffer cells and macrophages is likely generally
advantageous for improving virus pharmacology for liver and systemic therapy. Since dendritic cells also express scavenger receptors,30,31 evading phagocytosis by any antigen presenting cell may
reduce adaptive responses against Ad and its transgene products.

Materials and Methods
Cell culture. Human embryonic kidney cells (293) were purchased from

Microbix (Toronto, Ontario, Canada). A549 Human Lung Carcinoma
cells (ATCC CCL-185; ATCC, Manassas, VA) and RAW 264.7 murine
monocyte-macrophage cells (ATCC CRL-2278) were purchased from the
American Type Culture Collection (ATCC). All cells were maintained in
Dulbecco’s modified Eagle’s medium containing 10% heat-inactivated fetal
calf serum (Gibco, Carlsbad, CA) and penicillin/streptomycin at 100 U/ml
(Gibco).

Adenoviruses. Ad5GL and Ad5dsRed: First-generation, replication-defec-

tive (E1 and E3 deleted) Ad5 vectors carrying enhanced green fluorescent
protein and luciferase fusion gene (GL) or dsRed were produced with the
AdEasy system (Qbiogene, Irvine, CA/MP Biomedicals, Solon, OH) in 293
cells as described previously.16
Ad6: Wild type Ad6 (ATCC).
Ad5/6GL: Ad6 viral genomic DNA was purified using a PureLink Viral
RNA/DNA Mini Kit (Invitrogen, Carlsbad, CA) and the HVR cassette was
amplified by PCR (F primer 5′-TACTTTGACATCCGCGGCGTGCTGG-3′
and R primer 5′-GTGGGGCCATGGGGAAGAAGGTGGCG-3′), cut
with ApaI and PstI and cloned into the Ad5GL backbone. 293 cells were
transfected with the full-length recombined construct using Polyfect reagent
(Qiagen, Valencia, CA). All viruses were purified on two consecutive CsCl
gradient centrifugations, desalted using Econopac 10-DG chromatography
columns (Bio-Rad, Hercules, CA), resuspended in 0.5 mol/l sucrose in
KPBS and stored at −80 °C. Viral particle concentration was determined by
A260 measurements. Viral plaque forming units and TCID50 was determined
by serial dilution of virus on 293 cells. Typical yields for Ad5 and Ad5/6
were 3.4 × 1012 and 6.4 × 1011 vp/ml. Particle/plaque forming units (TCID50)
ratios were 108 and 404 for Ad5GL and Ad5/6GL, respectively.
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Helper-dependent adenoviral vectors: The chimeric helper virus
AdNG177 contains the Ad6 HVR region in an otherwise serotype 5
genome and was constructed by replacing the 6710 bp Sfi I fragment in
the serotype 5 helper virus AdNG16332 with the 6815 bp Sfi I fragment
from Ad5/6GL. HDAd5/6-GL was produced by coinfecting 116 cells
with AdNG177 and HD5-GL22 as described in detail elsewhere.33
HDAd5/6-hFIX was produced by coinfecting 116 cells with AdNG177
and HDD21.7E4PEPCK-hFIX-WL34 as described in detail elsewhere.33
All vector particle numbers were determined by absorbance at 260 nm
and confirmed by real-time PCR. Transduction of different vectors was
compared by luciferase assay.
Animals. Female BALB/c, C57BL/6 or male Syrian hamsters were purchased

from Harlan Sprague-Dawley (Indianapolis, IN). They were housed in the
Mayo Clinic Animal Facility under the Association for Assessment and
Accreditation of Laboratory Animal Care (AALAC) guidelines with animal
use protocols approved by the Mayo Clinic Animal Use and Care Committee.
All animal experiments were carried out according to the provisions of the
Animal Welfare Act, PHS Animal Welfare Policy, the principles of the NIH
Guide for the Care and Use of Laboratory Animals, and the policies and procedures of Mayo Clinic. Blood was collected from the cheek in BD Microtainer
tubes and serum was separated by centrifugation for 1 minutes at 16,000g.

Ad injections. All viruses were diluted in PBS but were brought up in different volumes depending on the route of injection. For mice: i.n. (10 µl
in left nare), i.m. (50 µl total, 25 µl per hind leg muscle), and i.v. (100 µl in
the tail vein). In hamsters: i.m (200 µl total, 100 µl per hind leg muscle),
and i.j. (intrajugular; 200 µl in the jugular). For predosing, mice were first
injected i.v. with 3 × 1010 vp of Ad5dsRed in 100 µl of PBS 4 hours before
i.v. injection of 1 × 1010 vp of Ad5GL or Ad5/6GL. For toxicity experiments,
2.5 × 1011 vp was injected i.v. For LDH assay, up to 1 × 1011 vp was injected
i.v. For FIX experiments, 2.5 × 1010 vp was injected i.v. For all other experiments, mice were injected with a total viral dose of 1 × 1010 vp.
Warfarinization. Mice were injected subcutaneously with 133 µg warfarin
in 100 µl peanut oil both 3 days and 1 day prior to i.v. injection of Ad.
In vivo bioluminescence imaging. Mice and hamsters were anesthetized with ketamine/xylazine and injected intraperitoneally with 100 µl
(for mice) or 200 µl (for hamsters) of d-luciferin (20 mg/ml; Molecular
Imaging Products, Bend, OR). Animals were imaged on the Lumazone
Imagine System (Photometrics, Roper Scientific, Tucson, AZ) for 1–10
minutes with 1 × 1 or 2 × 2 binning using no filters or photomultiplication.
Lumazone imaging software was used to determine total light intensity per
mouse (photons/second) for data analysis.
SPR analyses. FX protein was purchased from Hematologic Technologies

(Essex Junction, VT). Ad5GL and Ad5/6GL hexon was purified from
supernatants of CsCl virus preparations. Hexon protein was further purified and buffer exchanged on a 10G and then G-75 Sephadex column
(Bio-Rad) into Hank’s buffered salt solution. Hexon and FX protein was
immobilized onto research grade CM5 sensor chips using the Biacore 2000
instrument and the amine coupling reagents (Biacore, Pittsburgh, PA). All
data was collected in replicates of three for each concentration of analyte.

In vitro luciferase assay. To detect luciferase expression in vitro, CHO,
CHO-CAR, SKOV3, and RAW 264.7 cells were plated to 80–90% confluency in 96-well plates and infected with varying multiplicities of infection of Ad vectors. After a 24 hours incubation at 37 °C, cells were lysed
with cold passive lysis buffer (Promega, Madison, WI). Luciferase assay
reagent was added and relative luminescence units was measured with the
Beckman Coulter DTX 880 Multimode Detector system.
Uptake of virus into RAW 264.7. RAW 264.7 cells were seeded to 85–90%

confluency in 24 well plates and virus was applied to cells at an multiplicity of infection 10,000 for 24 hours. Media and noncell bound virus was
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removed and cells were harvested. DNA was extracted using the DNeasy
Blood and Tissue kit according to the manufacturer’s protocol (Qiagen)
with an RNase A digestion. Real-time PCR was performed as described
below for both viral [cytomegalovirus (CMV)] and cellular (GAPDH)
genomic targets. Reactions were performed in triplicate with uninfected
cellular DNA as the negative control.
In vivo vector genome quantification. Mice were injected with varying

doses of Ad vectors. After 1 or 24 hours, animals were euthanized and 20 ng
of the large liver lobe was harvested. DNA was extracted using the DNeasy
Blood and Tissue kit according to the manufacturer’s protocol (Qiagen)
with an RNase A digestion. Real-time PCR was performed as described
below for both viral (CMV) genomic targets. Reactions were performed in
triplicate with a PBS injected mouse as the negative control.

Quantitative real-time PCR. Concentration of DNA samples was

determined by Abs260 and then diluted to 20 ng/µl. Real-time PCR
was performed on the DNA in an Applied Biosystems Prism 7900HT
sequence detection system with SDS 2.3 software. Each well contained
10 µl Sybr Green (Applied Biosystems, Warrington, UK), 1 µl H2O,
2 µl of 3 µmol/l F Primer, 2µl of 3 µmol/l R Primer, and 5 µl sample (i.e.,
100 ng DNA/well). The parameters used were one cycle of 95 °C for 15
minutes, and 40 cycles of 95 °C for 15 seconds, 55 °C for 1 minute, and
72 °C for 30 seconds. To normalize data, PCR was done for both the
cellular housekeeping gene GAPDH (using previously published F
primer 5′-CGTGTTCCTACCCCCAATGT-3′ and R primer 5′-TGTC
ATCATACTTGGCAGGTTTCT-3′) and viral CMV gene (F primer 5′-CA
AGTGTATCATATGCCAAGTACGCCCC-3′ and R primer 5′-CCCCGT
GAGTCAAACCGCTATCCACGCC-3′).16 Viral DNA was normalized to
cellular DNA by dividing CMV genomes by GAPDH genomes.
Immunohistochemistry. BALB/c mice were injected i.v. with PBS or Ad
vectors at a low dose (1 × 1010 vp) or at a high dose (3 × 1010 vp). After 6
hours, the large liver lobe was harvested and incubated over night at room
temperature in formalin. Tissue was embedded in paraffin and cut to 4 µm
sections. These were probed with rat anti-F4/80 primary (MCA497EL;
AbD Serotec, Raleigh, NC) at a 1:200 dilution and ah horseradish peroxidase-conjugated anti-rat secondary, with DAB substrate. Quantifying positively stained cells: Images of five fields of view for each mouse section were
taken. The ImageJ software was used to convert them to binary images, and
the “Threshold” feature was used to separate out positively stained cells
from background nuclei. “Analyze particles” was used to count numbers of
stained regions (25-infinity).
Determination of serum IL-6, ALT, and hFIX levels. Serum was collected
at 6 hours after injection and IL-6 levels were quantified using an OptEIA
ELISA kit (BD Biosciences, San Diego, CA) according to the manufacturer’s
protocol. The amount of IL-6 was determined by measuring absorbance at
450 nm and compared to a standard curve with known IL-6 concentration.
Serum was collected at 72 hours and ALT was quantified using the Alanine
Aminotransferase kit (Biotron Diagnostics, Hemet, CA) according to the
manufacturer’s protocol. Serum was collected 7 days after injection and
hFIX levels were analyzed by ELISA (Enzyme Research Laboratories,
South Bend, IN) according to the manufacturer’s protocol.
LDH assay. Serum was collected from BALB/c mice 30 minutes after i.v.
injection with varying doses of Ad vector. LDH levels were measured
within 24 hours using the Liquid Reagent kit (Pointe Scientific, Canton,
MI) and decreasing all volumes by fivefold due to small serum collections.
LDH activity was measured by incubation at 37 °C and reading the absorption at 340 nm with a spectrophotometer.
Data analysis. Graphs and statistical analyses were performed using Prism
Graphical software. Analysis between two and three groups was determined by unpaired t-test, and one-way ANOVA (Newman–Keuls posttest), respectively.
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SUPPLEMENTARY MATERIAL
Figure S1. Design and characterization of adenoviral constructs.
Table S1. Ad5/6GL grows to lower particle and infectious unit titers
compared to Ad5GL.
Table S2. Ad5/6 hexon has lower affinity for Factor X (FX) compared
to Ad5 hexon.
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Table S1. Replication defective Ad5/6GL grows to lower particle and infectious unit titers
compared to Ad5GL.
RD-Ad5GL
12

RD-Ad5/6GL HD-Ad5GL HD-Ad5/6GL HD-Ad6GL
11

Concentration (vp/ml)

3.4x10

6.4x10

3.5x1012

6.6x1012

2.2x1012

Particle: PFU

212

1391

nd

nd

nd

Particle:TCID50

108
404
nd
nd
RD = replication defective; HD = helper-dependent; GL = GFPLuc; nd = not determined

nd

1

Table S2. Adenovirus (Ad) 5/6 hexon has lower overall binding affinity for Factor X (FX)
compared to Ad5 hexon. KD = equilibrium rate constant; Ka = association rate constant; Kd =
dissociation rate constant.
Hexon

Ad5

Ad6

Ad5

Ad5/6

KD (M)

Ka (1/Ms)
-8

1.59 x 10

-7

2.35 x 10

-9

1.68 x 10

-8

1.63 x 10

3

9.76 x 10

3

8.20 x 10

5

1.90 x 10

5

1.54 x 10

Kd (1/s)

Method

-4

FX affixed to chip, Ad
particles flowed over

-3

FX affixed to chip, Ad
particles flowed over

1.53 x 10

1.69 x 10

-4

3.04 x 10

-3

2.50 x 10

Ad (purified) hexon
affixed to chip, FX
flowed over
Ad (purified) hexon
affixed to chip, FX
flowed over

2

